Skip to Main Content

Paper Details

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
J Immunother Cancer
20
2022
Author NameAffiliation
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison
  • 1 - 1

Datasets

Release 1.2